The Cost of Delay: Why Fertility Needs a Stronger Policy Response

The central failure in fertility policy is not simply whether care exists, but when people are able to access it. In fertility, delay is not a neutral administrative issue; it shapes outcomes, widens inequity, increases the likelihood of more invasive treatment, and can permanently narrow the window in which intervention is effective. Yet across the NHS, fertility care is still too often treated as though time is incidental. Birth rates have fallen to historic lows, with the total fertility rate in England and Wales around 1.41 children per woman [1]. That is not merely a demographic trend; it is a strategic warning that the UK requires a more coherent, time-sensitive policy response.

This is not only about choice, but also about constraints 

People do not typically arrive at ‘fewer children than we hoped for’ because of one decision. They arrive there because the conditions for starting a family have become harder, later, and more uncertain, from childcare costs and workplace policies to housing pressures. In parallel, delayed parenthood collides with biological realities that are still poorly understood by many in the public and too rarely discussed in routine care. The average age of first-time mothers in England and Wales is now 29.4 years [2], and the average age of women seeking IVF is around 35 [3].

Demand is rising, but the system responds too late 

That pressure is already visible across fertility services. In 2023, around 1 in 32 births in the UK were conceived via IVF [3], underlining the growing role of assisted conception in family formation and the sustained demand being placed on services. Yet patient experience and access remain inconsistent. National survey findings point to friction throughout the NHS pathway, including delays in starting treatment, variable GP confidence, and waiting lists that push intervention further into time-sensitive reproductive years [4]. A system that responds late in this context does not merely inconvenience patients; it compounds clinical, emotional, and economic cost.

Inequity is built into commissioning

The postcode lottery is not a rhetorical phrase; it is measurable. NICE recommends three full IVF cycles for eligible women under 40, yet in practice, many ICBs still fund only one cycle and some fund two, leaving only a small minority aligned with national guidance [12,13]. This matters because cumulative live birth rates improve over multiple complete cycles, so restricting access at one cycle is not a neutral commissioning choice; it reduces the chance of success [14]. A further mismatch exists earlier in the pathway: although NICE defines fertility problems as failure to conceive after 12 months of regular unprotected intercourse, many local policies still require two years before NHS-funded IVF is offered [12,13]. For some groups, particularly women over 35, that delay can be clinically significant because reproductive potential declines with age [12,14].

Fertility literacy is weak, and misinformation fills the gap 

Reproductive health education still often omits practical, time-sensitive realities, including infertility, miscarriage, endometriosis, and PMOS (formerly PCOS; polycystic ovary syndrome) [6]. In some communities, infertility is also associated with shame, silence, or perceived stigma for both women and men, which can make people less likely to speak openly or seek timelysupport [10,11]. When reliable education is absent, people turn to online sources. One analysis cited found that only 11% of fertility-related social media posts were credible [7]. For population health, that translates into delayed help-seeking, avoidable escalation, and poorer outcomes. 

Fertility should be treated as a public health issue, not only a specialist service issue 

This is not just a treatment issue; it is also a prevention and public health issue. If the previous section describes the information gap, the policy response is to address fertility awareness earlier and more systematically. Better education would not remove structural barriers, but it could support earlier help-seeking, more informed reproductive decision-making, and timelier referral into care, particularly when reproductive health conditions such as endometriosis or ovulatory disorders are present. Framed in this way, fertility awareness should not sit solely within specialist services; it should be recognised as part of a wider public health approach to women’s health, prevention, and health education across the life course.

The economic case is being undervalued

The case for action is not only clinical and social; it is also economic. A declining birth rate contributes to an ageing population, a shrinking workforce and rising dependency ratios, placing long-term pressure on public services [8]. Yet fertility interventions are often assessed through short-term cost lenses. Economic modelling cited in recent analysis suggests strong returns; for example, one European study estimated that in 2016, every euro spent on IVF returned about €15.98 [9]. If we continue to value fertility only up to the point of birth, we will keep making decisions that appear efficient in-year but are strategically costly over time.

What this means for leaders in practice:

• NHS leaders: treat fertility as time-sensitive care, reduce variation in referral pathways, improve early advice, and design for prevention across the life course.

• Policymakers: align strategy across education, childcare, workplace policy and commissioning; fertility cannot be ‘fixed’ by the NHS alone.

• Pharmaceutical industry: move beyond product-only narratives towards system value, prevention, pathway redesign, equity and long-term outcomes.

If the UK is serious about prevention, equity and NHS sustainability, fertility can no longer remain peripheral within women’s health policy. The next phase of reform should bring together commissioning, education, earlier intervention, and pathway redesign within a coherent cross-system strategy. I would welcome engagement with NHS, ICB and policy leaders, alongside responsible life sciences partners, on what a credible and measurable fertility strategy should look like in practice. 

To read more, subscribe to our newsletter to get alerted when we release GPN's upcoming report, Not Just Menopause: Pharmacy’s Role in Women’s Health Inequalities Across the Life Course or visit globalpolicynetwork.com/reports to read our other reports.

References (Vancouver style) 

1. Office for National Statistics. Births in England and Wales: 2024 (refreshed populations). 2025. 

2. Office for National Statistics. Milestones: journeying through modern life. 2024. 

3. Human Fertilisation and Embryology Authority. Fertility treatment 2023: trends and figures. 2025. 

4. Human Fertilisation and Embryology Authority. National Patient Survey 2024. 2024. 

5. Integrated Care Board fertility funding alignment with NICE recommendations (as cited in UK fertility consensus analysis). September 2025. 

6. K, et al. Reproductive health education in the schools of the four UK nations: is it falling through the gap? 2023. 

7. Dhanoya T, et al. #misinformation: The perils of using social media for medical advice regarding infertility. Human Fertility. 2025;28(1). 

8. World Bank. Age dependency ratio (persons aged under 15 or over 64 per 100 working-age people aged 15–64). 2024. 

9. Matorras R, et al. Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: a global perspective. Best Pract Res Clin Obstet Gynaecol. 2023. 

10. Lee J, Kim S, Nam SH. Living with silence and shame: a meta-synthesis of women’s lived experiences of infertility-related stigma. Int J Womens Health. 2025;17:2699-2713. 

11. Gerrits T, Kroes H, Russell S, van Rooij F. Breaking the silence around infertility: a scoping review of interventions addressing infertility-related gendered stigmatisation in low- and middle-income countries. Sex Reprod Health Matters. 2022;30(1):2134629. 

12. National Institute for Health and Care Excellence. Fertility problems: assessment and treatment. NICE guideline NG257. Published 31 March 2026. 

13. Department of Health and Social Care. NHS-funded in vitro fertilisation (IVF) in England. GOV.UK. Updated 11 September 2025. 

14. McLernon DJ, Steyerberg EW, te Velde ER, Lee AJ, Bhattacharya S. Predicting the chances of a live birth after one or more complete cycles of in vitro fertilisation: population based study of linked cycle data from 113,873 women. BMJ. 2016;355:i5735.